What changed from existing technology?
This study found that a protein called IRAK1 helps cancer cells resist treatment with chemotherapy and the body's immune system. When this protein is turned off, the cancer cells become more sensitive to these treatments.
This study is the first to identify IRAK1 as a key regulator of both chemoresistance and immuno-killing in non-small cell lung cancer, revealing a novel molecular mechanism underlying the chemoimmunoresistant phenotype.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
nosis in the TCGA-LUAD cohort and in early-stage NSCLC patients. The IRAK1/ABCB1/ABCC1highABCA1low signature was predictive of poor response to chemotherapy a
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings suggest that targeting IRAK1 could be a potential strategy to overcome chemoresistance and improve the effectiveness of immunotherapy in non-small cell lung cancer patients.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.